| |
|
Key factsELARA Management Supervisory Board Scientific Advisory Board Prof. Frank Giles Founders
|
About elara Pharmaceuticals GMBhELARA is an early stage drug discovery and development company, incorporated 2006 in Germany. Based on outstanding scientific research, which originates from the European Molecular Biology Laboratory (EMBL) in Heidelberg, ELARA’s mission is to provide novel and efficacious medicines for the treatment of cancers with high unmet medical need. Seed capital was invested by EMBL Ventures and intellectual property licensed via EMBL Enterprise Management (EMBLEM). ELARA is located on the EMBL campus in close proximity to the founders' labs, with medicinal chemistry established at the Chem2Biz facility at the BASF. ELARA is supported by the German Federal Ministry of Education and Research (BMBF) under its GO-Bio initiative. Management
Dr. Bernd Janssen, CSO (interim) has more than 25 years of experience in drug discovery, research management and international collaborations. He has held various leadership and management positions in the pharmaceutical industry, most recently as Director Medicinal Chemistry with Abbott Laboratories, and previously with BASF Pharma. As a graduate from the University of Bonn, Dr. Janssen earned his Ph.D. in Chemistry from the Ruhr University of Bochum (Germany). He has co-authored more than 50 patent applications and scientific papers, revealing his inventive contributions to Dermatology, Oncology and Immunology. He was also awarded the first BASF Innovation Prize for his seminal role in successfully moving a discovery project to the market. Dr. Janssen is member of several academic and industrial advisory boards. ELARA Supervisory Board
Dr. David Owen O.B.E
After graduating with a Ph.D. in pharmacology, Dr. Owen
held various R&D positions in the pharmaceutical industry
for 20 years (Sandoz and SmithKline). Before joining the MRC,
in 1990, to led technology transfer activities, he led technology
driven licensing agreements for SK&F, as Group Director, Compound
& Technology Acquisitions. At the MRC, Dr. Owen led initiatives
to develop technology transfer such that the MRC achieved an excellent
reputation for its activities in patenting, licensing technologies,
creating new “start-up” companies and generation of
revenues. He was a founder and first Chairman of MVM Ltd., the
MRC linked investment Fund that has raised more than £140
million to invest in early stage companies. In June 2001 he was
appointed OBE for “services to medical research and technology
transfer”. ELARA Scientific Advisory BoardProf. Frank Giles is Professor of Medicine and Chief of the Division of Hematology and Medical Oncology at the University of Texas Health Science Center, San Antonio and Director of the Institute of Drug Development (IDD) at the Cancer Therapy & Research Center and Director of the Experimental Therapeutics Program of the San Antonio Cancer Institute. He has authored over 400 peer-reviewed articles on research into developmental therapeutics for patients with cancer. Prior to this, Prof. Giles was Chief of the Section of Developmental Therapeutics at MD Anderson Cancer Center and Co-Chair of the Division of Cancer Medicine Phase I Group. His research focuses on the development of novel therapies for patients with cancer with a focus on targeted therapies. Prof. Giles received his Doctorate in Medicine from the National University of Ireland. |
|
|
|
© 2008, Elara Pharamceuticals. All rights reserved. |
|
|
Designed by mbhstudios.com |
|
Dr.
Christof Antz is managing partner at EMBL Ventures. He
has extensive experience in managing start-up and early-phase
biotech companies. In 1998, he co-founded Otogene (Tübingen
and Seattle), and went on to serve as CEO at Abeta (Heidelberg)
before joining EMBL Ventures in 2003. Dr. Antz obtained his Ph.D.
in physics/structural biology at the Max-Planck-Institute for
Medical Research (Heidelberg).